Compound: Amrinone
SMILES: O=c1[nH]cc(-c2ccncc2)cc1N
InChIKey: RNLQIBCLLYYYFJ-UHFFFAOYSA-N
Synonyms: Amrinone, 60719-84-8, inamrinone, Cartonic, Amcoral, Vesistol, Amrinona, Amrinonum, WIN 40680, [3,4'-Bipyridin]-6(1H)-one, 5-amino-, DTXSID9022603, 5-Amino(3,4'-bipyridin)-6(1H)-one, NSC-759805, CHEBI:2686, JUT23379TN, (3,4'-BIPYRIDIN)-6(1H)-ONE, 5-AMINO-, C01CE01, 3-amino-5-(pyridin-4-yl)pyridin-2-ol, 5-Amino[3,4'-bipyridin]-6(1H)-one, DTXCID602603, Amrinon, 3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one, Win40680, 5-Amino-(3,4'-bipyridine)-6(1H)-one, RefChem:388796, 262-390-0, Wincoram, Inocor, Cordemcura, 5-Amino-[3,4'-bipyridin]-6(1H)-one, Win-40680, Amrinonum [INN-Latin], Amrinona [INN-Spanish], 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone, 3-amino-5-pyridin-4-yl-1H-pyridin-2-one, 5-Amino-(3,4'-bipyridin)-6(1H)-one, AWD 08-250, MFCD00083228, Amrinone [INN], MLS000069829, 5-amino-3,4'-bipyridin-6(1H)-one, SMR000058850, CHEMBL12856, NCGC00164379-01, CAS-60719-84-8, 3-Amino-5-(4-pyridinyl)-1,2-dihydro-2-pyridone, Inamrinone (USP), Amcoral (TN), CCRIS 3794, Amrinone (JAN/INN), Inamrinone [USAN:USP], EINECS 262-390-0, BRN 0744819, UNII-JUT23379TN, Inamrinone;, Prestwick_44, Amrinone (Standard), 3-amino-5-pyridin-4-ylpyridin-2-ol, Spectrum_001350, AMRINONE [JAN], AMRINONE [MI], AMRINONE [VANDF], 3-amino-5-(4-pyridyl)-1H-pyridin-2-one, Opera_ID_1054, Prestwick0_000800, Prestwick1_000800, Prestwick2_000800, Prestwick3_000800, Spectrum2_001980, Spectrum3_000956, Spectrum4_001069, Spectrum5_000999, INAMRINONE [USAN], AMRINONE [MART.], INAMRINONE [VANDF], AMRINONE [USP-RS], AMRINONE [WHO-DD], Epitope ID:613412, cid_3698, SCHEMBL44012, BSPBio_000940, KBioGR_001398, KBioSS_001830, 5-25-15-00181 (Beilstein Handbook Reference), MLS001074083, DivK1c_000136, SPECTRUM1503084, SPBio_002139, SPBio_002879, BPBio1_001034, GTPL7202, orb1309182, SCHEMBL13457017, BDBM34651, HMS500G18, HY-B1294R, KBio1_000136, KBio2_001830, KBio2_004398, KBio2_006966, KBio3_002052, INAMRINONE [USP IMPURITY], NINDS_000136, GLXC-08115, HMS1570O22, HMS2097O22, HMS2234F12, HMS3264E16, HMS3369J10, HMS3714O22, INAMRINONE [USP MONOGRAPH], Pharmakon1600-01503084, HY-B1294, Tox21_112110, Tox21_301847, CCG-39487, EBC-12099, NSC759805, STK590307, AKOS005512516, Tox21_112110_1, DB01427, FA17893, KS-5178, NSC 759805, IDI1_000136, NCGC00016896-01, NCGC00016896-02, NCGC00016896-03, NCGC00016896-04, NCGC00016896-06, NCGC00095984-01, NCGC00255137-01, AC-12186, AC-33137, SY112917, 3-amino-5-(4-pyridyl)hydropyridin-2-one, 5-Amino(3,4'-bipyridine)-6-(1H)-one, 3-Amino-5-(4-pyridinyl)-2(1H)pyridinone, CS-0013064, NS00001039, ST51014892, 5-AMINO-3,4'-BIPYRIDYL-6(1H)-ONE, C75837, D00231, 5-Amino-1,6-dihydro-6-oxo-[3,4'-bipyridine], AB00052312-04, AB00052312_05, EN300-6477374, F220489, Q422724, SR-00000002445, SR-00000002445-2, BRD-K45924332-001-04-4, BRD-K45924332-001-07-7, BRD-K45924332-001-16-8, Z1198150288, 5-Amino-[3,4 inverted exclamation mark -bipyridin]-6(1H)-one, Amrinone, United States Pharmacopeia (USP) Reference Standard
Theoretical properties:
molecular_formula: C10H9N3O
molecular_weight: 187.20 g/mol
exact_mass: 187.074561919 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 1
heavy_atom_count: 14
topological_polar_surface_area: 68 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 294-297
solubility: 5.60e+00 g/L
Descriptions:
pubchem: Amrinone is a 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure. It has a role as a cardiovascular drug and an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor.
chebi: A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
chembl: INAMRINONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Amrinone, also known as inamrinone, and sold as Inocor, is a pyridine phosphodiesterase 3 inhibitor.  It is a drug that may improve the prognosis in patients with congestive heart failure. Amrinone has been shown to increase the contractions initiated in the heart by high-gain calcium induced calcium release (CICR). The positive inotropic effect of amrinone is mediated by the selective enhancement of high-gain CICR, which contributes to the contraction of myocytes by phosphorylation through cAMP dependent protein kinase A (PKA) and Ca2+ calmodulin kinase pathways.